Share
Print
Accelerating the development of prophylactic vaccines against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
Details
Location:Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Cote d'Ivoire, Dem. Rep. Congo, Equatorial Guinea, Eritrea, Eswatini (Swaziland), Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe
Funding agency:
Grantmaking entity type:Development Institution
Description
Topic updates
19 September 2025
PROPOSAL NUMBERS
Call HORIZON-JU-GH-EDCTP3-2025-01-two-stage has closed on 03.09.2025.
27 proposals have been submitted.
The breakdown per topic is:
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage:12
Evaluation results are expected to be communicated in January 2026.
11 July 2025
EVALUATION RESULTS (STAGE 1)
Published: 10/01/25
Deadline: 20/03/25
Available budget: EUR 122.700.000
In accordance with the call conditions, the evaluation of the first-stage proposals was made looking only at the criteria 'Excellence' and 'Impact'. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set for each topic/type of action with separate call-budget-split at a level that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget (and not below 2.5 times the budget):
- HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage: 9 points
The results of the evaluation for each topic are as follows:
|
|
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage |
|
Number of proposals submitted (including proposals transferred from or to other calls) |
18 |
|
Number of inadmissible proposals |
0 |
|
Number of ineligible proposals |
2 |
|
Number of above-threshold proposals |
12 |
|
Total budget requested for above-threshold proposals |
175.977.587,13 € |
Summary of observer report:
The evaluations were in the estimation of both observers impartial, fair and equitable. No issues of confidentiality were seen to arise.
This was, in particular, enabled by a careful selection of experts and recorders as well as ensuring that any experts or recorders with a COI were excluded from the discussions of the proposal in question. The use of the SEP platform for all aspects of the reports (IER, CR and QC) also reinforced the confidentiality of the evaluation.
No issues of non-conformity were observed and the evaluation followed all the applicable rules. The eligibility of proposals was determined by the Unit prior to the assignment of experts to proposals. Any issues of proposals being not being “in scope” were discussed by the experts during the consensus meetings.
We recently informed the applicants about the evaluation results for their proposals.
For questions, please contact applicants@global-health-edctp3.europa.eu
GENERALISED FEEDBACK for successful applicants after STAGE 1
In order to best ensure equal treatment, successful stage 1 applicants do not receive the evaluation summary reports (ESRs) for their proposals, but this generalised feedback with information and tips for preparing the full proposal.
Information & tips
Unlike in first stage proposals, the budget table included in second stage proposals should indicate the total costs of the project and not only the contribution requested from Global Health EDCTP3 Joint Undertaking. You should therefore include in your costs (in each cost category and in the total costs) the amounts that are covered by contributions from contributing partners.
Please also specify clearly and separately in your proposal the amounts covered by contributing partners for each contributing partner involved. If such amounts are not provided for the project as a whole but only a specific work package/activities, please indicate it too.
In the explanation of resources allocation, please keep in mind that the evaluation of “Quality and efficiency of the implementation” will be based on the following award criteria:
- Quality and effectiveness of the work plan, assessment of risks, and appropriateness of the effort assigned to work packages, and the resources overall.
- Capacity and role of each participant, and the extent to which the consortium as a whole brings together the necessary expertise
Join the networking platform and find the right partners and co-funders to maximise the chances of your proposal at the second stage. Discover more and register.
Please bear in mind that your full proposal will now be evaluated more in-depth and possibly by a new group of outside experts.
Please make sure that your full proposal is consistent with your short outline proposal. It may NOT differ substantially. The project must stay the same.
25 April 2025
Call HORIZON-JU-GH-EDCTP3-2025-01-two-stage_stage1 has closed on the 20/03/2025.
The breakdown per topic is:
HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage: 18 proposals
Evaluation results are expected to be communicated in July 2025
Accelerating the development of prophylactic vaccines against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
TOPIC ID: HORIZON-JU-GH-EDCTP3-2025-01-NTD-03-two-stage
Type of grant: Call for proposals
General information
Programme: Horizon Europe (HORIZON)
Call: HORIZON-JU-GH-EDCTP3-2025-01-two-stage (HORIZON-JU-GH-EDCTP3-2025-01-two-stage)
Type of action: HORIZON-JU-RIA HORIZON JU Research and Innovation Actions
Type of MGA: HORIZON Action Grant Budget-Based [HORIZON-AG]
Status: Forthcoming
Deadline model: two-stage
Planned Opening Date: 30 January 2025
Deadline dates:
20 March 2025 17:00 (Brussels time)
02 September 2025 17:00 (Brussels time)
Topic description
Expected Outcome:
Background
Neglected Tropical Diseases (NTDs) represent a challenge to public health, particularly in the African continent, where their prevalence is intertwined with socio-economic disparities. In January 2021, the WHO published the report “Ending the neglect to attain the sustainable development goals: a roadmap for neglected tropical diseases 2021-2030” followed by 2024 WHO Global report which is the second in a series of global reports describing progress towards the 2030 targets set in the road map for neglected tropical diseases 2021–2030. The road map sets global targets and milestones to prevent, control, eliminate or eradicate 20 diseases and disease groups as well as cross-cutting targets aligned with the Sustainable Development Goals. Three foundational pillars will support global efforts to achieve the targets: accelerate programmatic action (pillar 1), intensify cross-cutting approaches (pillar 2) and change operating models and culture to facilitate country ownership (pillar 3). The overarching global targets described in this report, in line with the SDGs and the WHO's 13th General Programme of Work are to ensure 90% fewer people requiring interventions against NTDs, 75% fewer NTD-related DALYs and 100 countries achieving elimination of at least one NTD and eradication of two NTDs (Dracunculiasis and Yaws).
2023 Annual WHO African region report mentions: “ Nineteen countries in the WHO African Region have successfully eliminated at least one NTD, with Togo notably eliminating four: Guinea worm disease, lymphatic filariasis, human African trypanosomiasis (HAT) (gambiense), and trachoma".
As progress is made on the therapeutics front with tangible impact from EDCTP2 investments, it has been increasingly evident that vaccine development represents a very valuable solution. Today, Dengue, Chikungunya and Rabies are the only NTDs that can be prevented through vaccination, but cost and availability still limit their more widespread use. Moreover, the development of NTD vaccines, including those for schistosomiasis, leishmaniasis, leprosy, hookworm, and Chagas disease are led by nonprofit product development partnerships with a need for more funds to address translational activities.
In this context, the Global Health EDCTP3 programme is aiming to contribute significantly to the fight against NTDs and alleviate the disease burden in Africa aligning with SDGs and fostering improved health outcomes for the most vulnerable populations. It aims to unite the collective intersectoral efforts ofresearchers, policymakers, and healthcare practitioners, ensuring inclusivity for all.
Expected Outcome
This topic aims at supporting activities that contribute to one or several of the expected impacts for this call. Proposals submitted under this topic should aim for delivering results that are directed, tailored towards and contributing to following one of the expected outcomes:
- Generate data on novel or existing vaccines (Phase II/Phase III trials) to make progress towards prevention, control and elimination of NTDs in SSA (note: in case of no or limited vaccine candidates in development, early development is encouraged (Phase I onwards);
- Improve the understanding of barriers for progression of new or improved vaccines against NTDs through the R&D pipeline;
- Generate clinical data including pregnant and lactating women, new-borns, children, adolescents, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in SSA as relevant.
Scope:
Scope
The objective of the topic is to progress the development of prophylactic vaccines against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa.
Proposals should carry out early and/or late-stage clinical studies to evaluate the safety, immunogenicity, efficacy in Africa in NTDs. The NTDs in scope of Global health EDCTP3 list are: Buruli ulcer, dengue and chikungunya, dracunculiasis (guinea-worm disease), echinococcosis, foodborne trematodiases, human African trypanosomiasis (sleeping sickness), leishmaniases, leprosy (Hansen disease), lymphatic filariasis, mycetoma, onchocerciasis (river blindness), rabies, schistosomiasis, soil-transmitted helminthiases, taeniasis/cysticercosis, trachoma, and yaws. NTDs out of scope are: Chagas, chromoblastomycosis and other deep mycoses, scabies and other ectoparasites, and snakebite envenoming. Proposals should identify clearly which NTD(s) they are targeting.
Research on development of integrated preventive measures across NTDs is strongly encouraged.
Combined approaches embracing vector control and vaccine development targeting the host/reservoir in the context of One Health are applicable. However, implementation research is out of scope for this topic.
Proposals are to generate clinical data on prophylactic vaccines in the general population and/or, when relevant, include pregnant and lactating women, new-borns, children, adolescents, other vulnerable and neglected populations, and people with co-infections and co-morbidities at risk in SSA. Relevant determining characteristics (sex, gender, age, socio-economic status, etc.) are to be considered. Where possible, collaboration and coordination with the Team Europe Initiative on Manufacturing and Access to Vaccines, medicines and health products (TEI-MAV+) or similar African initiatives is encouraged. The applicants could show, for example, willingness to enter into technology transfer agreements with African counterparts - including the provision of patents, technical knowledge and know-how -, or early engagement with regulators or with African manufacturers to support the translation into affordable products adapted to the regional market.
Proposals should clearly describe the desired target product profile. Applicants need to concisely describe any prior relevant research findings and explain how the proposal builds on available data (including data generated in scope of earlier EDCTP programmes if available). Full details of the development milestones, including specific go/no-go criteria for the implementation of the proposed clinical trial(s) must be included, as well as specific plans for the subsequent regulatory approval process, which should aim at obtaining relevant market authorisation and an access strategy that will allow patients in low-resource settings to access the final product.
The applicants are encouraged to consider new adaptive trial designs and lessons learnt from COVID-19 potentially allowing for shorter development timelines.
Proposals should engage communities and relevant stakeholders, most notably (local) key opinion leaders, researchers, health care professionals, policy makers, public health authorities and end-users. Applicants should provide methodologies for translating research findings into public health practice and policy guidelines and, if relevant, market exploration plans.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from sub-Saharan African countries, including involvement of Franco/Lusophone countries, if possible. Collaboration with other international research groups with relevant experience is very much encouraged. Applicants are also reminded of the expectationof reaching out to organisations in countries with relatively lower research capacities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, such as external conferences, workshops or symposiums for an exchange of knowledge, and best practices with external collaborators.
The purpose of this topic is to fund a varied portfolio of projects tackling different diseases. The granting authority will therefore base its funding decision relevant to this topic on the ranking of the proposals taking into account diversity of the respective diseases targeted in the proposals that are graded above thethreshold.
General conditions
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
The conditions are described in General Annex B except for the specific conditions for the Global Health EDCTP3 JU funding as regards entities eligible for funding and consortium composition, the specific rule for countries where the coordinator may be established and the obligation to designate a scientific project leader as below.
Specific conditions replacing the relevant sections in General Annex B to the Horizon Europe Work Programmes.
A. Entities eligible for funding
This section applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
To become a beneficiary, legal entities must be eligible for funding. To be eligible for funding, applicants must be established in one of the following countries:
- The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;
- The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);
- Countries associated to Horizon Europe[1]: Albania, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo[2], Moldova, Montenegro, New Zealand (associated to Pillar II 'Global Challenges and European Industrial Competitiveness' as from the Work Programmes 2023 onwards, including for the institutionalised European partnerships), North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom;
- Until association agreements start producing legal effects either through provisional application or their entry into force, transitional arrangements apply. The transitional arrangements apply, at the time of the adoption of this Work Programme, with regard to the following countries and legal entities established in these countries, with which association negotiations are being processed or where association is imminent):Morocco.
- The following countries which are constituent states of the EDCTP Association [3]: Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Eswatini, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.
Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call/topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
Entities established in low- and middle-income countries that are not members of the EDCTP Association and listed in the Horizon Europe List of Participating Countries on the Funding & Tenders Portal [4] are not eligible for funding unless the specific country in which the entity is established, is associated to Horizon Europe or if the participation of the entity is considered essential for implementing the action by the granting authority.
B. Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the Global Health EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
- At least three legal entities independent from each other and each established in a different country, where legal entities are eligible to receive funding;
- At least one independent legal entity established in a Member State, or in an associated country to Horizon Europe that is a member of the EDCTP Association; and
- At least one independent legal entity established in a sub-Saharan African country that is a member of the EDCTP Association.
This condition applies to both Research and Innovation Actions (RIA) and Coordination and SupportActions (CSA).
For the two CSA topics, i.e. topic HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage and topic HORIZON-JU-GH-EDCTP3-2025-03-NETWORKS-01-two-stage - according to which the EDCTP Association is obligatorily part of the consortium as coordinator, the EDCTP Association must not be counted as one of the three independent legal entities necessary to ensure the eligibility of the consortium composition.
Specific cases:
Affiliated entities — Affiliated entities are eligible for funding if they are established in one of the countries listed above, or in a country identified in the specific call/topic conditions.
Associated partners — Entities not eligible for funding and therefore not able to participate as beneficiaries or affiliated entities (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[5], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the coordinator of the indirectaction must be established in a Member State or associated country, or South Africa.
Scientific project leader
If the coordinator is not established in a country in SSA (please see previous paragraph), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity. The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
- During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;
- Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;
- Act as the key contact point for the Global Health EDCTP3 JU regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, without prejudice to the tasks entrusted directly to the coordinator as per the Model Grant Agreement;
- Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;
- Review the action’s deliverables and reports before their submission by the coordinator;
- Lead the work packages(s) related to the tasks of scientific project leadership.
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the Global Health EDCTP3 JU on all issues of interest for the proper scientific management of the action.
[1] The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding & Tenders Portal for up-to-date information on the current list and on the position for Associated Countries: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf
[2] This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
[3] The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website www.edctp.org
[4] Horizon Europe List of Participating Countries on the Funding & Tenders Portal https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf
[5] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014. OJ L 427, 30.11.2021, p. 17–119; Regulation - 2021/2085 - EN - EUR-Lex (europa.eu).
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Additionally to General Annex F, the following is taken into consideration for the evaluation procedure and ranking: The purpose of this topic is to fund a varied portfolio of projects tackling different diseases. The granting authority will therefore base its funding decision relevant to this topic on the ranking of the proposals taking into account diversity of the respective diseases targeted in the proposals that are graded above the threshold. It may therefore fund in priority proposals that are ranked lower than others, if they target another relevant disease that is not tackled yet among the higher ranked proposals.
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
Specific conditions related to Scores and weighting
Replacing the scores and weighting section in General Annex D to the Horizon Europe Work Programmes as regards second stage of two-stage evaluations, for both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA)
Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criterion 3 (Quality and Efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene, for the first stage of the two-stage evaluation of both RIAs and CSAs, the scores and weightingas indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2025 apply.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085 establishing52, grants awarded under this topic will have to include in their Plan for the exploitation and dissemination of results including communication activities to be submitted during the project as a deliverable also the following:
Access plan
Participants must include in their Plan for the exploitation and dissemination of results an appropriate and proportionate access plan that demonstrates their strategies to ensure that the products and services that they develop based or partly based on the results of clinical studies undertaken by their project are affordable, available and accessible to the public (market and end-users) at fair and reasonable conditions. This covers registration targets, plans to meet demand, flexible approaches to IP, engagement with regulators and manufacturers where relevant and other strategies that reflect ability to pay and ensures that economic barriers to access are low. In addition, participants should add, if relevant, as part of the plan, an outline on how to achieve the optimal use of an intervention including, for example, how to avoid irrational use, overuse or abuse (e.g. antimicrobials).
Additionally to any updates during the project, a final version of the Plan for the exploitation and dissemination of results including the above access plan, must also be submitted with the final report of the project.
Also in line with Article 114 of the Council Regulation 2021/2085, participants will be subject to the following additional exploitation obligations:
- Participants must – up to four years after the end of the action (see Data Sheet, Point 1) – use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants’ best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.
- In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non- exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.
- In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.
- For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product and any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.
described in Annex G of the Work Programme General Annexes.
Specific conditions
JU right to object to transfer/exclusive licensing
The Global Health EDCTP3 JU may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5 of the Model Grant Agreement. In addition, in accordance with Article 24(3) of Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe [1] and the Model Grant Agreement, the right toobject applies also to participants that have not received funding from the JU.
[1]Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17.
Other requirements
For all projects under this topic, if the coordinator is not from a country in SSA, the designation of a scientific project leader with the roles as described in the introduction is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity.
Annual Work Programme 2025
Global Health EDCTP3 Calls for proposals
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Note: despite blind evaluation being mentioned in the standard application form for stage 1 proposals, available in the Funding and Tenders Portal (at the stage of adoption of this Work Programme), please note that this call is not part of the ‘blind evaluation pilot’, therefore no anonymisation is required for stage 1proposals of the two-stage calls.
Standard application form (HE RIA IA Stage 1)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA and CSA Stage 1)
Guidance
HE Programme Guide
Model Grant Agreements (MGA)
HE MGA
Call-specific instructions
Information on financial support to third parties (HE)
Information on clinical studies (HE)
Additional documents:
HE Main Work Programme 2023–2025 – 1. General Introduction
HE Main Work Programme 2023–2025 – 4. Health
HE Main Work Programme 2023–2025 – 13. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Start submission
The submission system is planned to be opened on the date stated on the topic header.
Get support
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
Similar grants
By Locations
Funding agency:
EC
Status:
awarded
Location:
Algeria, American Samoa, Angola, Anguilla, Antigua and Barbuda, Argentina, Aruba, Australia, Bahamas, Barbados, Belize, Benin, Bermuda, Bolivia, Botswana, Brazil, British Virgin Islands, Burkina Faso, Burundi, Cameroon, Cape Verde, Caribbean Netherlands, Cayman Islands, Central African Republic, Chad, Chile, Christmas Island, Cocos (Keeling) Islands, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Cote d'Ivoire, Cuba, Dem. Rep. Congo, Djibouti, Dominica, Commonwealth of, Dominican Republic, Easter Island, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Eswatini (Swaziland), Ethiopia, Falkland Islands, Fiji, French Guiana, French Polynesia, French Southern Territory, Gabon, Galapagos, Gambia, Ghana, Grenada, Guadeloupe, Guam, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Heard and McDonald Islands, Honduras, Jamaica, Kenya, Kiribati, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Marshall Islands, Martinique, Mauritania, Mauritius, Mayotte, Mexico, Micronesia, Montserrat, Morocco, Mozambique, Namibia, Nauru, New Caledonia, New Zealand, Nicaragua, Niger, Nigeria, Niue, Norfolk Island, Northern Mariana Islands, Palau, Panama, Papua New Guinea, Paraguay, Peru, Pitcairn, Puerto Rico, Reunion, Rwanda, Saint Helena, Saint Kitts and Nevis, Saint Lucia, Saint Martin, Saint Vincent and the Grenadines, Samoa, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, St. Pierre and Miquelon, Sudan, Suriname, Tanzania, Togo, Tokelau, Tonga, Trinidad and Tobago, Tunisia, Turks and Caicos, Tuvalu, Uganda, Uruguay, US Virgin Islands, Vanuatu, Venezuela, Wallis and Futuna, Western Sahara, Zambia, Zimbabwe
Funding agency:
Horizon Europe
Status:
awarded
Location:
EU 27, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Cote d'Ivoire, Dem. Rep. Congo, Equatorial Guinea, Eritrea, Eswatini (Swaziland), Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Uganda, Zambia, Zimbabwe
By Sectors
Funding agency:
EC
Status:
awarded
Location:
Kosovo
Funding agency:
Horizon 2020
Status:
awarded
Location:
EU 27, Switzerland
grant Background
About the Funding Agency
Horizon Europe will incorporate research and innovation missions to increase the effectiveness of funding by pursuing clearly defined targets.
The Commission has engaged policy experts to develop studies, case studies and reports on how a mission-oriented policy approach will work.
Mission areas
5 mission areas have been identified, each with a dedicated mission board and assembly. The board and assembly help specify, design and implement the specific missions which will launch under Horizon Europe in 2021.
- Adaptation to climate change including societal transformation
- Cancer
- Climate-neutral and smart cities
- Healthy oceans, seas, coastal and inland waters
- Soil health and food
About the Sectors
Health
Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.
Key areas:
- Healthcare services and facilities
- Public health and disease prevention
- Medical equipment, supplies, and services
Research & Innovation
Focuses on collecting data, generating new knowledge, and applying it to develop improved methods, technologies, products, and solutions across sectors.
Key areas:
- Scientific research, studies, and investigations
- Innovation programs and applied R&D initiatives
- Technology development
- Space-related research and exploration themes
Locations
Angola
In recent years, Angola has stepped up investment in repairing, expanding and modernising its infrastructure as a core pillar of post‑civil war reconstruction and economic development. While high levels of public investment have helped restore key transport, energy and water assets, improving the efficiency and quality of this investment will require strengthening financial markets, regulatory frameworks and infrastructure governance. According to InfraCompass 2020, Angola scores relatively low on these institutional drivers compared with many other countries, underscoring the importance of reforms to translate funding into sustainable economic outcomes.
Nr. of tenders: 9387
Nr. of grants: 3010
Nr. of donors: 598
Nr. of jobs: 29
Nr. of tenders: 9387
Nr. of grants: 3010
Nr. of donors: 598
Nr. of jobs: 29
Benin
Benin has been increasing both public and private investment in strategic infrastructure to support economic transformation and regional integration. Major initiatives include expansion of the Port of Cotonou and its logistics capacity to strengthen trade linkages across West Africa, significant public‑transport redevelopment financed with multilateral support, and agricultural infrastructure projects that link rural production with markets. The government is pursuing reforms to improve the investment climate and establish public‑private partnership (PPP) frameworks, supported by development policy financing from the World Bank and concessional loans to bolster economic governance and private sector participation. Continued improvements in transport, energy access, and economic diversification remain central to deepening productivity and inclusive growth.
Nr. of tenders: 13031
Nr. of grants: 3207
Nr. of donors: 710
Nr. of jobs: 37
Nr. of tenders: 13031
Nr. of grants: 3207
Nr. of donors: 710
Nr. of jobs: 37
Frequently Asked Questions
Haven't found what you're looking for? Get in touch with us using our contact page.
Where can I find international grant opportunities?
DevelopmentAid collects grant opportunities from bilateral donors, multilateral agencies, foundations, and international organizations in one centralized platform.
Who can apply for grants listed on DevelopmentAid?
Grants are typically open to NGOs, civil society organizations, research institutions, public entities, and sometimes private organizations or consortia.
Does DevelopmentAid help with grant applications?
DevelopmentAid does not write or submit applications, but it provides access to full call details, guidelines, deadlines, and donor information needed to apply.